Pharmacotherapy
Severity of CKD-associated pruritus linked to all-cause mortality, other comorbidities
The severity of chronic kidney disease-associated pruritus may be linked with higher risks of all-cause mortality, hospitalizations, cardiovascular events and infections, data show.
OSA pharmacotherapy reduces disease severity
A combination pharmacotherapy for obstructive sleep apnea led to greater reductions in disease severity compared with placebo, according to results from a proof-of-concept phase 2 trial.
FDA grants breakthrough device designation to digital therapeutic for schizophrenia
The FDA has granted breakthrough device designation for CT-155, an investigational prescription digital therapeutic co-developed by Click Therapeutics and Boehringer Ingelheim to treat negative symptoms of schizophrenia.
At Issue: The implications of SELECT on CVD prevention in high-risk patients with obesity
The SELECT trial, which showed semaglutide, a GLP-1 receptor agonist also approved for diabetes, reduced CV events in people with overweight/obesity and CVD but no diabetes, was one of the most important developments in cardiology in 2023.
Addressing pediatric obesity: The crucial role of parenting
Pediatric obesity has become a significant health concern in recent years, with the prevalence reaching higher levels. It is a complex condition influenced by various factors, including genetics, lifestyle choices and environmental factors.
One in four adults use pharmacologic therapies for chronic pain
One in four adults relied solely on medications to manage chronic pain, highlighting an opportunity to increase use of nonpharmacologic therapies, particularly in men, older adults and those with public insurance, according to researchers.
Lifestyle medicine foundation for treating people with obesity
DENVER — Lifestyle medicine is a central component of obesity treatment, including for adults who receive anti-obesity medications or undergo bariatric surgery, according to three speakers at the Lifestyle Medicine Conference.
Lack of awareness, treatment of high cholesterol more common among Black, Hispanic adults
Among U.S. adults with elevated LDL, being unaware and untreated was more common among Black and Hispanic adults and those with lower income or without health insurance, data from the National Health and Nutrition Examination Survey show.
Q&A: Addressing lack of safe, effective smoking cessation therapies
Although a recent report from the CDC showed that cigarette smoking in 2021 is the lowest it has been since 1965, millions of people continue to smoke, with many struggling to quit with the current authorized treatments.
Pharmacotherapy plus measurement-based care improves depression outcomes
Measurement-based care decreased depression severity, promoted remission and improved medication adherence among patients with depressive disorders treated with pharmacotherapy, according to a study.